We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are three stocks with buy rank and strong value characteristics for investors to consider today, October 29th:
Pampa Energia S.A. (PAM - Free Report) : This integrated electricity company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 32.8% over the last 90 days.
Sappi Limited (SPPJY - Free Report) : This woodfibre company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its next year earnings rising 4.6% over the last 60 days.
Jounce Therapeutics, Inc. : This clinical-stage immunotherapy company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising more than 100% over the last 90 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Top Ranked Value Stocks to Buy for October 29th
Here are three stocks with buy rank and strong value characteristics for investors to consider today, October 29th:
Pampa Energia S.A. (PAM - Free Report) : This integrated electricity company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 32.8% over the last 90 days.
Pampa Energia S.A. Price and Consensus
Pampa Energia S.A. price-consensus-chart | Pampa Energia S.A. Quote
Pampa Energia has a price-to-earnings ratio (P/E) of 3.5, compared with 17.6 for the industry. The company possesses a Value Score of A.
Pampa Energia S.A. PE Ratio (TTM)
Pampa Energia S.A. pe-ratio-ttm | Pampa Energia S.A. Quote
Sappi Limited (SPPJY - Free Report) : This woodfibre company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its next year earnings rising 4.6% over the last 60 days.
Sappi Ltd. Price and Consensus
Sappi Ltd. price-consensus-chart | Sappi Ltd. Quote
Sappi has a price-to-earnings ratio (P/E) of 4.04, compared with 10.3 for the industry. The company possesses a Value Score of A.
Sappi Ltd. PE Ratio (TTM)
Sappi Ltd. pe-ratio-ttm | Sappi Ltd. Quote
Jounce Therapeutics, Inc. : This clinical-stage immunotherapy company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising more than 100% over the last 90 days.
Jounce Therapeutics, Inc. Price and Consensus
Jounce Therapeutics, Inc. price-consensus-chart | Jounce Therapeutics, Inc. Quote
Jounce Therapeutics has a price-to-earnings ratio (P/E) of 2.32, compared with 9 for the industry. The company possesses a Value Score of B.
Jounce Therapeutics, Inc. PE Ratio (TTM)
Jounce Therapeutics, Inc. pe-ratio-ttm | Jounce Therapeutics, Inc. Quote
See the full list of top ranked stocks here.
Learn more about the Value score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>